BridgeBio Oncology Therapeutics (BBOT) Assets (2023 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Assets of $417.6 million for Q1 2026, down 6.85% sequentially from $448.4 million in Q4 2025, and up 113.44% YoY from $195.7 million in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Assets (2023 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Assets for 4 years, with the latest figure at $417.6 million in Q1 2026.
- Quarterly Assets rose 113.44% year-over-year to $417.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $417.6 million (up 113.44% YoY) and the FY2025 annual result came in at $448.4 million, up 172.9% from the prior year.
- Assets fell to $417.6 million in Q1 2026 per BBOT's latest filing, from $448.4 million in the prior quarter.
- Over five years, Assets peaked at $484.8 million in Q3 2025 and troughed at $332894.0 in Q4 2023.
- A 4-year average of $247.8 million and a median of $194.0 million in 2024 frame the typical range for Assets.
- The sharpest annual moves came in 2024 and 2025: Assets soared 49255.35% in 2024, then gained 3.96% in 2025.
- Over 4 years, Assets stood at $332894.0 in 2023, then jumped by 49255.35% to $164.3 million in 2024, then soared by 172.9% to $448.4 million in 2025, then fell by 6.85% to $417.6 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $417.6 million, $448.4 million, and $484.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 376.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 376.71 Mn |
| Mar 31, 2026 | 417.65 Mn |
| Dec 31, 2025 | 448.38 Mn |
| Sep 30, 2025 | 484.79 Mn |
| Jun 30, 2025 | 197.39 Mn |
| Mar 31, 2025 | 195.68 Mn |
| Dec 31, 2024 | 164.30 Mn |
| Sep 30, 2024 | 192.33 Mn |
| Jun 30, 2024 | 189.87 Mn |
| Mar 31, 2024 | 187.53 Mn |
| Dec 31, 2023 | 332,894.00 |